Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13684MR)

This product GTTS-WQ13684MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13684MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3738MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ3286MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ7836MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ3778MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ13959MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1693MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ4416MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ8169MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HL036337
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW